Beryl Drugs Ltd

On 27-Feb, Beryl Drugs Ltd witnessed a significant decline in its share price, dropping by 8.05% to close at ₹20.00. This sharp fall reflects a broader trend of underperformance relative to both its sector and the benchmark Sensex index, compounded by high intraday volatility and weakening investor participation.

Beryl Drugs Ltd's latest Q3 FY26 results are poor, showing a net loss of ₹0.17 crores and a 28.81% decline in revenue year-on-year, indicating significant operational challenges and decreased market competitiveness. The company's financial health is concerning, with negative operating margins and low return on equity.

Beryl Drugs Ltd's latest results show a 6.89% sequential sales growth to ₹5.12 crores, but an 8.73% year-over-year decline, with low profitability reflected in a PAT margin of just 0.20%. Overall, the company faces challenges in sustaining revenue growth and improving profitability.

As of 19-Nov, Beryl Drugs Ltd is facing a decline in its stock price, currently at Rs 22.25, down 4.79%, with a significant year-to-date drop of 38.45%. The stock is underperforming compared to the Sensex, indicating a bearish trend and lack of investor interest.

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

As of 29-Oct, Beryl Drugs Ltd's stock price is Rs 24.00, up 4.35% recently, but it has a significant year-to-date decline of 33.61%. Despite short-term gains, investor participation has dropped notably, indicating potential concerns about sustained interest.

As of 07-Oct, Beryl Drugs Ltd's stock price is Rs 22.75, down 5.17%, and has underperformed its sector by 5.48%. The stock has a year-to-date decline of 37.07% and lacks identifiable catalysts for its current downward trend.

As of 06-Oct, Beryl Drugs Ltd is currently priced at 23.99, reflecting a 2.3% increase. The stock has shown strong short-term performance, gaining 7.82% over the past week, although it remains down 33.64% year-to-date compared to the Sensex's rise.

As of 26-Sep, Beryl Drugs Ltd's stock price has declined to Rs 22.39, down 5.73%, with a total loss of 7.44% over the last two days. The stock has underperformed its sector and shows a bearish trend, with significant drops in investor participation and a year-to-date decline of 38.06%.

As of 24-Sep, Beryl Drugs Ltd is seeing a price increase to Rs 24.24, up 5.39%, and has outperformed its sector recently. However, it has a significant year-to-date decline of -32.95%, indicating weak long-term fundamentals despite recent gains.

As of 23-Sep, Beryl Drugs Ltd is currently priced at 23.00, reflecting a short-term increase but a significant year-over-year decline of -36.11%. Despite attractive valuations, the company faces long-term challenges that may deter investors.

As of 22-Sep, Beryl Drugs Ltd is currently priced at 22.98, reflecting a slight increase today but a significant year-to-date decline of 36.43%. Despite recent underperformance compared to the Sensex, the stock has shown strong long-term growth, outperforming the benchmark over the past three years.

As of 19-Sep, Beryl Drugs Ltd's stock price is declining at 22.61, down 4.07%, with a year-to-date return of -37.46%. The company is underperforming its sector and the broader market, reflecting weak fundamentals and declining investor interest.